Hyper‐Intense Tumor Peripheral Accumulation of Antibody‐Conjugated Iron Oxide Nanoparticles can Enable Breast Cancer Detection by Magnetic Particle Imaging
Aug 2026· Advancement of science· 0 citations· 43 references
Medicine
TL;DR
Iron oxide nanoparticle‐mediated MPI has the potential to detect tumors, providing another powerful diagnostic tool, and was observed to distinguish tumors from general inflammation.
Abstract
ABSTRACT Targeting nanoparticles to cancer cells in vivo remains a challenge for cancer imaging. We assessed nanoparticle distribution after injecting iron oxide nanoparticles conjugated with either a monoclonal anti‐HER2 (human epidermal growth factor 2), or a non‐specific IgG antibody into a human HER2 overexpressing murine breast cancer model. We used Magnetic Particle Imaging (MPI) and histopathology to assess particle localization at 72 h after injection. MPI detects magnetic moments produced by magnetic particles, and histology enables spatial quantification of nanoparticles. Intratumor iron content measured by MPI correlated with inductively coupled plasma mass spectrometry (ρ = 0.868, p < 0.0001). We detected nanoparticle accumulation in tumors, and organs and tissues associated with inflammation. MPI showed higher uptake of nanoparticles in tumors, regardless of their performance in vitro. Spatial analysis showed that 43 ± 7% of nanoparticles that reached the tumor accumulated in the peripheral quartile of the tumor, with decreasing amounts toward the center. Immunohistochemical analysis showed the nanoparticles were strongly associated with inflammatory immune and stromal cells in the tumor microenvironment. This hyperintense peripheral accumulation, or ring pattern, observed with MPI enabled us to distinguish tumors from general inflammation. Iron oxide nanoparticle‐mediated MPI has the potential to detect tumors, providing another powerful diagnostic tool.
Non-invasive tracking of natural killer (NK) cells remains a major challenge in cancer immunotherapy, limiting our understanding of their in vivo migration and persistence. Magnetic particle imaging (MPI) offers a quantitative, real-time method for visualizing labeled cells, yet optimal labeling protocols for NK cells...
Suzanne E. Lightsey, Victoria Consalvo, Sk Rajab Ali et al.· Biomaterials Science· 0 citations
Early-stage hepatocellular carcinoma diagnosis is hindered by the inability of conventional MRI to concurrently detect tiny tumors and delineate their microvascular networks. To address this, we engineered sequence-programmable iron oxide nanoparticles with precisely tuned magnetic properties that enable dual-phase T1-...
Tian-Ming Cui, Yun Xu, Wei-Tao Yang et al.· Small· 0 citations
BSA@Au/Tb-FA exhibited favorable in vitro hemocompatibility and biocompatibility, with enhanced cellular uptake in MDA-MB-231 and complementary enhanced SPCCT/MRI contrast under phantom conditions, supporting its potential as a bimodal imaging agent.
Yusuf O. Ibrahim, Nabil Maalej, A. Raja et al.· International Journal of Nan...· 0 citations
In vivo characterization and visualization of tumors often relies on radioactive tracers and expensive, complex equipment, which limits the frequency of analysis, throughput, and accessibility. Short-wave infrared (SWIR) fluorescence is a new nonradioisotopic imaging modality with flexible readouts at high depth and hi...
Feng-Yuan Xu, Wonseok Lee, Kai-Chi Shi et al.· Bioconjugate chemistry· 0 citations
QDs are highlighted as complementary optical probes that may bridge the resolution gap between whole-body imaging and cellular-scale analysis, with particular relevance for preclinical research, ex vivo tissue interrogation, and intraoperative imaging.
An RGD-mediated active-targeted imaging nanoprobe based on lanthanide nanoparticles with a core-shell structure that can be used for actively targeted NIR-II fluorescence/T1-MRI dual-modal imaging of breast cancer, providing a promising tool for image-guided surgery.
Yu-Chen Guo, Hong-Xia Yue, Xin-Jing Liu et al.· Dalton Transactions· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.